Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MG-K10 in children aged 6 to <12 years with moderate-to-severe atopic dermatitis
CTR20264078Phase 2Active
- Sponsor
- Medigene AG
- Start
- Oct 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of comekibart in atopic dermatitis (AD), sponsored by Medigene AG. Started Oct 2026; status: active.
02
Drugs
comekibart
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on CTR20264078.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20264078.